Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Selective inhibitors of cyclo‐oxygenase‐2 have been shown to be effective anti‐inflammatory drugs with reduced gastrointestinal toxicity relative to conventional nonsteroidal anti‐inflammatory drugs (NSAIDs). In the present study, we examined the possibility that selective COX‐2 inhibition, by blocking prostacyclin synthesis, would increase blood pressure and cause leukocyte adherence and platelet aggregation. Normal rats and rats with hypertension induced by chronic administration of N ω‐nitro‐L‐arginine methylester were given celecoxib (10 mg kg−1) daily for 3 weeks. Celecoxib significantly elevated of blood pressure in both the normal and hypertensive rats (mean increase of >33 mm Hg after 3 weeks). In normal rats, celecoxib had no effect on serum 6‐keto prostaglandin (PG)F 1α levels. Hypertensive rats exhibited a significant increase (82%) in serum 6‐keto PGF 1α levels, and this was reduced to the levels of normal rats by treatment with celecoxib. Rats treated with celecoxib exhibited significant increases in weight gain (20%), plasma arginine‐vasopressin levels (148%) and plasma urea (69%) relative to vehicle‐treated controls. Plasma creatinine levels were unaffected by treatment with celecoxib, while plasma renin levels were significantly decreased (30%) relative to controls. Superfusion of mesenteric venules with celecoxib (3 μ M) in vivo resulted in significant increases in leukocyte adherence to the endothelium in both normal and hypertensive rats. These studies suggest that suppression of COX‐2 significantly influences vascular and/or renal function, leading to elevated blood pressure and leukocyte adherence. British Journal of Pharmacology (2000) 129, 1423–1430; doi:10.1038/sj.bjp.0703232
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FLOWER, R. J., & VANE, J. R. (1972) · Nature · doi:10.1038/240410a0 · Cited by 779 · cited 1×
“The existence of multiple forms of cyclo-oxygenase, the key enzyme in the biosynthesis of prostaglandins, was ®rst suggested in 1972 (Flower & Vane, 1972).”
Background
Cited by
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346)
Wallace, J. L., Caliendo, G., Santagada, V., & Cirino, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00611.x · Cited by 231
Self-citationDrug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity
Perazella, M. A. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200306000-00006 · Cited by 225
Hostynek, J. J., Dreher, F., & Maibach, H. I. (2010) · Inflammation Research · doi:10.1007/s00011-010-0214-4 · Cited by 22
Metadata
- Authors
- Muscará, M. N., Vergnolle, N., Lovren, F., Triggle, C. R., Elliott, S. N., Asfaha, S., & Wallace, J. L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-04
- Volume
- 129
- Issue
- 7
- Pages
- 1423-1430
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2063842505
- Cited by
- 125
- References
- 1
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. https://app.cochat.ai/papers/10.1038/sj.bjp.0703232
- The paper
- Muscará, M. N., Vergnolle, N., Lovren, F., Triggle, C. R., Elliott, S. N., Asfaha, S., & Wallace, J. L. (2000). Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0703232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.